|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:activities
|
insulin receptor agonist
|
|
gptkbp:availability
|
prescription only
|
|
gptkbp:average_temperature
|
refrigerated
|
|
gptkbp:brand
|
gptkb:Tresiba
|
|
gptkbp:climax
|
no peak
|
|
gptkbp:clinical_trial
|
Phase 3
basal insulin therapy
BEGIN study
BOOST study
DEVOTE trial
DURATION study
ONSET study
|
|
gptkbp:color
|
clear
|
|
gptkbp:contraindication
|
severe hypoglycemia
hypersensitivity to insulin degludec
|
|
gptkbp:dosage_form
|
gptkb:software_framework
|
|
gptkbp:duration
|
long-acting
|
|
gptkbp:education
|
proper injection technique
recognize hypoglycemia symptoms
diet and exercise importance
monitor blood glucose
|
|
gptkbp:effective_date
|
gptkb:2015
|
|
gptkbp:form
|
injection
|
|
gptkbp:frequency
|
once daily
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Tresiba
|
|
gptkbp:indication
|
gptkb:Type_1_diabetes
Type 2 diabetes
|
|
gptkbp:ingredients
|
gptkb:insulin_degludec
|
|
gptkbp:interacts_with
|
gptkb:ACE_inhibitors
diuretics
beta-blockers
thiazolidinediones
|
|
gptkbp:is_used_for
|
diabetes management
|
|
gptkbp:lifespan
|
25 hours
|
|
gptkbp:manager
|
subcutaneous
|
|
gptkbp:manufacturer
|
gptkb:Novo_Nordisk
|
|
gptkbp:origin
|
gptkb:Denmark
|
|
gptkbp:packaging
|
gptkb:tablet
vial
|
|
gptkbp:pharmacokinetics
|
subcutaneous absorption
glucose lowering effect
|
|
gptkbp:population
|
gptkb:Person
adults
|
|
gptkbp:premiered_on
|
1 hour
|
|
gptkbp:regulatory_compliance
|
gptkb:FDA
gptkb:EMA
TGA
|
|
gptkbp:side_effect
|
gptkb:lipodystrophy
allergic reactions
weight gain
injection site reactions
skin rash
hypoglycemia
edema
visual disturbances
|
|
gptkbp:website
|
upper arm
thigh
abdomen
buttocks
|
|
gptkbp:bfsParent
|
gptkb:Humulin
|
|
gptkbp:bfsLayer
|
4
|